Selected second quarter approvals.

Company

Approval

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)

FDA grants full approval to Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS)

ALK-Abello A/S (CSE:ALK-B)/Merck & Co. Inc. (NYSE:MRK)

FDA approves Grastek sublingual allergy immunotherapy tablet (AIT) to treat grass pollen-induced allergic rhinitis with or without conjunctivitis

ALK-Abello A/S (CSE:ALK-B)/Merck & Co. Inc. (NYSE:MRK)

FDA approves Ragwitek sublingual AIT to treat ragweed pollen-induced allergic rhinitis with or without conjunctivitis

Amgen Inc. (NASDAQ:AMGN)

FDA expands approval of Vectibix panitumumab for use in combination with FOLFOX chemotherapy as first-line treatment of metastatic colorectal cancer (mCRC) in patients with wild-type K-Ras (KRAS) tumors

AstraZeneca plc (LSE:AZN; NYSE:AZN)

FDA approves Epanova mixture of the free fatty acid forms of eicosapentaenoic acid and docosahexaenoic acid as an adjunct to diet and exercise to treat severe hypertriglyceridemia, defined as triglyceride levels ≥500 mg/dL

BioDelivery Sciences International Inc. (NASDAQ:BDSI)

FDA approves Bunavail buprenorphine naloxone as maintenance treatment for opioid dependence

Biogen Idec Inc. (NASDAQ:BIIB)/Swedish Orphan Biovitrum AB (SSE:SOBI)

FDA approves Eloctate (rFVIIIFc) to control and prevent bleeding episodes, for perioperative management and for routine prophylaxis in patients with hemophilia A

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

EC approves Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome)

Boehringer Ingelheim GmbH/Eli Lilly and Co. (NYSE:LLY)

EC approves Jardiance empagliflozin as an adjunct to diet and exercise to improve glycemic control in Type II diabetes

Cubist Pharmaceuticals Inc. (NASDAQ:CBST)

FDA approves Sivextro tedizolid to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA)

Durata Therapeutics Inc. (NASDAQ:DRTX)

FDA approves Dalvance dalbavancin to treat ABSSSIs caused by susceptible Gram-positive bacteria, including MRSA

Eli Lilly and Co. (NYSE:LLY)

FDA approves Cyramza ramucirumab as monotherapy for advanced stomach cancer or gastroesophageal junction adenocarcinoma following fluoropyrimidine- or platinum-containing chemotherapy

Genmab A/S (CSE:GEN; OTCBB:GMXAY)/GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

FDA expands approval of Arzerra ofatumumab to include first-line treatment of chronic lymphocytic leukemia (CLL)

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

EC approves Incruse umeclidinium as a once-daily, maintenance bronchodilator to relieve symptoms in chronic obstructive pulmonary disease (COPD)

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

FDA approves Incruse Ellipta umeclidinium bromide for maintenance treatment of airflow obstruction in COPD

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

FDA approves Tanzeum albiglutide to treat Type II diabetes as monotherapy or as add-on therapy

Greer Laboratories Inc./Stallergenes S.A. (Euronext:GENP)

FDA approves Oralair sublingual immunotherapy to treat grass pollen-induced allergic rhinitis with or without conjunctivitis

Johnson & Johnson (NYSE:JNJ)

FDA and EC approve Sylvant siltuximab to treat multicentric Castleman's disease in patients who are HIV-negative and human herpes virus 8 (HHV-8)-negative

MannKind Corp. (NASDAQ:MNKD)

FDA approves Afrezza inhaled insulin to improve glycemic control in Type I and II diabetics